Table 1. Patient characteristics.
| Median age (year) | 54.5 | (Range, 23–77) |
|---|---|---|
| Sex | ||
| Male | 18 | 75% |
| Female | 6 | 25% |
| EUTOS scorea | 36.2 | (Range, 3.5–119.0) |
| Low | 20 | 83.3% |
| High | 4 | 16.7% |
| Sokal scoreb | 0.84 | (Range, 0.58–11.42) |
| Low | 11 | 45.8% |
| Int | 9 | 37.5% |
| High | 4 | 16.7% |
| Time from diagnosis to treatment (days) | 12.5 | (Range, 4–37) |
| IS BCR-ABL1/ABL1 (%)c | 56.9±28.4 | |
| WBCs (per μl) | 96200±127700 | |
| Hb (g dl−1) | 12.7±2.6 | |
| Platelet (× 10a9/l) | 533±546 | |
| Additional chromosomal mutations | ||
| Yes | 2 Patient #2: Patient #4: | 8.3% t(8;17)(q11.2;q23) −Y |
| No | 22 | 91.7% |
| Achieving MMR at 2 years | ||
| Yes | 18 | 75.0% |
| Nod | 6 | 25.0% |
Abbreviations: MMR, major molecular response; WBCs, white blood cells.
a
EUTOS score:⩽87: low risk, >87: high risk.
b
Sokal score:⩽0.8: low risk, 0.8–1.2: intermediate risk, >1.2: high risk.
c
IS %BCR-ABL/ABL1 (%): % of BCR-ABL1 mRNA International Scale. Two patients with minor BCR-ABL1 mutations were excluded.
d
4 patients were still not achieving MMR and 2 patients were dropped out from this study.